Today Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical Company, Inc. The deal, which involves an upfront payment of $1.75 billion, will expand Boston Scientific’s electrophysiology and structural heart product portfolios—especially in the area of left heart access platforms.
“The talented and innovative Baylis Medical Company team, combined with these transseptal platforms, will enhance our efforts to improve procedural efficiencies with physician tools designed to make left atrial access safer and more predictable, with a focus on patient outcomes,” said Mike Mahoney, chairman and CEO of Boston Scientific in a company press release. “A leader in many of the fastest growing markets in our industry, we believe that Baylis Medical Company will add meaningful revenue, operating income, and new research and development capabilities across multiple Boston Scientific businesses, while complementing existing offerings within our electrophysiology and structural heart portfolios.”
The deal is expected to close in the first quarter of 2022.
Related Articles
-
“M.I.Tech is an innovator in nonvascular stent development, with product offerings that complement our existing stent portfolio.”
-
“We are pleased to expand our board of directors with two highly qualified executives from different sectors of the healthcare industry.”
-
Leslie Trigg, CEO of Outset Medical, is the new Chair of The Medical Device Manufacturers Association (MDMA) Board of Directors.
-
Baxter Hillrom is recalling its WatchCare Incontinence Management System (IMS) following reports that the radiofrequency emissions (RF) from WatchCare devices may interfere with other medical devices.
